RExercise limitation in interstitial lung disease - Mechanisms, significance and therapeutic options

Chronic Respiratory Disease

Volumn 7, Issue 2, 2010, Pages 101-111

  Holland, Anne E ^a,b  

^a LA TROBE UNIVERSITY   (Australia)

^b ALFRED HEALTH   (Australia)

Author keywords

Exercise; Interstitial; Lung diseases

Indexed keywords

ACETYLCYSTEINE; BOSENTAN; CORTICOSTEROID; COTRIMOXAZOLE; ETANERCEPT; MORPHINE; PIRFENIDONE; PLACEBO;

ARTERIAL OXYGEN TENSION; ASBESTOSIS; BREATHING MUSCLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIFFIUSE PARENCHYMAL LUNG DISEASE; DISEASE SEVERITY; EXERCISE; EXERCISE TOLERANCE; FIBROSING ALVEOLITIS; HEART FAILURE; HUMAN; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LOADING DRUG DOSE; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG VENTILATION; MUSCLE DISEASE; MUSCLE STRENGTH; NEBULIZATION; OXYGEN CONSUMPTION; OXYGEN THERAPY; OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; SARCOIDOSIS; SKELETAL MUSCLE; SPIROMETRY; TIDAL VOLUME; WALKING; DECISION MAKING; DISEASE COURSE; KINESIOTHERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

DECISION MAKING; DISEASE PROGRESSION; EXERCISE THERAPY; EXERCISE TOLERANCE; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; RESPIRATORY FUNCTION TESTS;

EID: 77952576038     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972309354689     Document Type: Review

References (65)

1. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest. 1999 ; 116: 1175-1182. (Pubitemid 29535966)
2. Burdon JG, Killian KJ, Jones NL Pattern of breathing during exercise in patients with interstitial lung disease. Thorax 1983 ; 38: 778-784. (Pubitemid 13019509)
3. DiMarco AF, Kelsen SG, Cherniack NS, Gothe B. Occlusion pressure and breathing pattern in patients with interstitial lung disease. Am Rev Respir Dis 1983 ; 127: 425-430. (Pubitemid 13083740)
4. Javaheri S., Sicilian L. Lung function, breathing pattern, and gas exchange in interstitial lung disease. Thorax 1992 ; 47: 93-97.
5. Marciniuk DD, Sridhar G., Clemens RE, Zintel TA, Gallagher CG Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. J Appl Physiol 1994 ; 77: 963-973. (Pubitemid 24258337)
6. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996 ; 109: 1566-1576. (Pubitemid 26193386)
7. Harris-Eze AO, Sridhar G., Clemens RE, Gallagher CG, Marciniuk DD Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994 ; 150: 1616-1622. (Pubitemid 24361736)
8. Agusti AG, Roca J., Gea J., Wagner PD, Xaubet A., Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991 ; 143: 219-225.
9. Miki K., Maekura R., Hiraga T., et al. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med 2003 ; 97: 482-490. (Pubitemid 36522722)
10. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003 ; 168: 1084-1090.
11. Agusti AG, Roca J., Rodriguez-Roisin R., Xaubet A., Agusti-Vidal A. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J 1988 ; 1: 510-516.
12. Risk C., Epler GR, Gaensler EA Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984 ; 85: 69-74. (Pubitemid 14215304)
13. Markos J., Musk AW, Finucane KE Functional similarities of asbestosis and cryptogenic fibrosing alveolitis. Thorax 1988 ; 43: 708-714.
14. Lee YC, Singh B., Pang SC, de Klerk NH, Hillman DR, Musk AW Radiographic (ILO) readings predict arterial oxygen desaturation during exercise in subjects with asbestosis. Occup Environ Med 2003 ; 60: 201-206. (Pubitemid 36269302)
15. Sette A., Neder JA, Nery LE, et al. Thin-section CT abnormalities and pulmonary gas exchange impairment in workers exposed to asbestos. Radiology 2004 ; 232: 66-74. (Pubitemid 38787821)
16. Sudduth CD, Strange C., Cook WR, et al. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med 1993 ; 95: 413-418. (Pubitemid 23303071)
17. Glaser S., Noga O., Koch B., et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 2009 ; 103: 317-324.
18. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006 ; 173: 744-750.
19. Bush A., Busst CM Cardiovascular function at rest and on exercise in patients with cryptogenic fibrosing alveolitis. Thorax 1988 ; 43: 276-283.
20. Gibbons WJ, Levy RD, Nava S., et al. Subclinical cardiac dysfunction in sarcoidosis. Chest 1991 ; 100: 44-50.
21. Nishiyama O., Taniguchi H., Kondoh Y., et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005 ; 127: 2028-2033. (Pubitemid 46260092)
22. Spruit MA, Thomeer MJ, Gosselink R., et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005 ; 60: 32-38. (Pubitemid 40101015)
23. Kabitz HJ, Lang F., Walterspacher S., Sorichter S., Müller-Quernheim J., Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006 ; 130: 1496-1502. (Pubitemid 44786745)
24. King TE, Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001 ; 164: 1171-1181.
25. Eaton T., Young P., Milne D., Wells AU Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005 ; 171: 1150-1157. (Pubitemid 40663728)
26. Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005 ; 99: 1431-1439.
27. Fell CD, Liu LX, Motika C., et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009 ; 179: 402-407.
28. Swigris JJ, Zhou X., Wamboldt FS, et al. Exercise SpO2 Accurately Reflects SaO2 and Predicts Mortality in Systemic Sclerosis. Thorax 2009 ; 64: 626-630.
29. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F., Sonett JR, Kawut SM Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006 ; 174: 659-664. (Pubitemid 44395333)
30. Caminati A., Bianchi A., Cassandro R., Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009 ; 103: 117-123.
31. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S., Shorr AF The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006 ; 100: 1734-1741. (Pubitemid 44283761)
32. Flaherty KR, Andrei AC, Murray S., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006 ; 174: 803-809. (Pubitemid 44511662)
33. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005 ; 25: 96-103. (Pubitemid 40207737)
34. Stephan S., de Castro Pereira CA, Coletta EM, Ferreira RG, Otta JS, Nery LE Oxygen desaturation during a 4-minute step test: predicting survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2007 ; 24: 70-76. (Pubitemid 350177775)
35. Erbes R., Schaberg T., Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997 ; 111: 51-57. (Pubitemid 27043606)
36. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998 ; 157: 1063-1072. (Pubitemid 28225169)
37. Bye PT, Anderson SD, Woolcock AJ, Young IH, Alison JA Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. Am Rev Respir Dis 1982 ; 126: 1005-1012.
38. Crockett AJ, Cranston JM, Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev 2001: CD002883.
39. Bradley B., Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008 ; 63 Suppl 5: v1 - v58.
40. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005 ; 171: 1040-1047. (Pubitemid 40616955)
41. King TE Jr, Behr J., Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008 ; 177: 75-81.
42. Raghu G., Brown KK, Costabel U., et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008 ; 178: 948-955.
43. Holland AE, Hill CJ, Conron M., Munro P., McDonald CF Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008 ; 63: 549-554. (Pubitemid 351831168)
44. Nishiyama O., Kondoh Y., Kimura T., et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008 ; 13: 394-399. (Pubitemid 351503129)
45. Varney VA, Parnell HM, Salisbury DT, Ratnatheepan S., Tayar RB A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther 2008 ; 21: 178-187.
46. Harris-Eze AO, Sridhar G., Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med 1995 ; 152: 1940-1945.
47. Lacasse Y., Goldstein R., Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006: CD003793.
48. Holland A., Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev 2008: CD006322.
49. Ferreira A., Garvey C., Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009 ; 135: 442-447.
50. Miller A., Brown LK, Sloane MF, Bhuptani A., Teirstein AS Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995 ; 107: 323-329.
51. Schwaiblmair M., Behr J., Fruhmann G. Cardiorespiratory responses to incremental exercise in patients with systemic sclerosis. Chest 1996 ; 110: 1520-1525. (Pubitemid 26425154)
52. Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997 ; 155: 1657-1664.
53. Fulmer JD, Roberts WC, von Gal ER, Crystal RG Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest 1979 ; 63: 665-676.
54. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007 ; 131: 217-222. (Pubitemid 46122996)
55. Flaherty KR, Mumford JA, Murray S., et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003 ; 168: 543-548. (Pubitemid 37088596)
56. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003 ; 168: 538-542.
57. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003 ; 168: 531-537. (Pubitemid 37088594)
58. Holland AE, Hill CJ, Conron M., Munro P., McDonald CF Small changes in six minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009 ; In press.
59. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007 ; 66: 169-173.
60. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002 ; 166: 111-117.
61. Moloney ED, Clayton N., Mukherjee DK, Gallagher CG, Egan JJ The shuttle walk exercise test in idiopathic pulmonary fibrosis. Respir Med 2003 ; 97: 682-687. (Pubitemid 36675672)
62. Dal Corso S., Duarte SR, Neder JA, et al. A step test to assess exercise-related oxygen desaturation in interstitial lung disease. Eur Respir J 2007 ; 29: 330-336. (Pubitemid 46231912)
63. Wells AU, King AD, Rubens MB, Cramer D., du Bois RM, Hansell DM Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997 ; 155: 1367-1375. (Pubitemid 27172785)
64. Garg R., Verma S. Pulse oximetry in scleroderma patients: concerns. Acta Anaesthesiol Scand. 2008 ; 52: 1303-1304.
65. Schunemann HJ, Guyatt GH Commentary - Goodbye M(C)ID! Hello MID, where do you come from? Health Services Research 2005 ; 40: 593-597.